Ardelyx (ARDX) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MeiraGTx (MGTX) has outperformed Ardelyx (ARDX) over the past year, gaining 27.1% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -26.5% for MGTX. MeiraGTx is the larger company by market cap ($1.01 billion vs $844.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | MGTX |
|---|---|---|
| Share price | $3.27 | $10.50 |
| Market cap | $844.27M | $1.01B |
| 1-day change | +0.31% | -2.96% |
| YTD return | -43.91% | +32.08% |
| 1-year return | -35.38% | +27.12% |
| 5-year return | +202.78% | -26.47% |
| P/E ratio (TTM) | — | 12.07 |
| Forward P/E | 11.26 | — |
| EPS (TTM) | $-0.23 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $15.35 |
| 52-week low | $3.18 | $6.62 |
| Distance from 52-week high | -61.07% | -31.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +294.50% | +164.29% |
| Average volume | 4.17M | 792.38K |
| Shares outstanding | 258.19M | 96.04M |
| Employees | 489 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed ARDX by 62.5 percentage points over the past year.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
ARDX vs MGTX FAQ
Which is bigger, Ardelyx or MeiraGTx?
MeiraGTx (MGTX) is larger, with a market capitalization of $1.01B compared with $844.27M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or MGTX?
MGTX returned +27.12% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and MeiraGTx in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Ardelyx and Biotechnology: Biological Products (No Diagnostic Substances) for MeiraGTx.